Literature DB >> 23517929

Nasal administration of drugs as a new non-invasive strategy for efficient treatment of multiple sclerosis.

Shaher Duchi1, Haim Ovadia, Elka Touitou.   

Abstract

We investigated the efficiency of nasal drug administration as a new non-invasive treatment strategy for MS. Glatiramer Acetate (GA) and GA-Cannabidiol (CBD) combination administered in nasal delivery system (NDS) resulted in a statistically significant decrease of clinical scores and inflammatory cytokine expression in experimental autoimmune encephalomyelitis (EAE) mice. Even a suboptimal dose of Prednisolone in NDS was effective in preventing the clinical signs of the disease. Neuron regeneration was observed in the hippocampus of EAE mice treated with GA-CBD in NDS. This work shows that nasal administration improved drug efficiency and stimulates further research for a non-invasive strategy for MS.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23517929     DOI: 10.1016/j.jneuroim.2013.02.013

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  16 in total

1.  Scrolls: novel microparticulate systems for enhanced delivery to/across the skin.

Authors:  Irit Allon; Elka Touitou
Journal:  Drug Deliv Transl Res       Date:  2016-02       Impact factor: 4.617

2.  Phospholipid Magnesome-a nasal vesicular carrier for delivery of drugs to brain.

Authors:  Hiba Natsheh; Elka Touitou
Journal:  Drug Deliv Transl Res       Date:  2018-06       Impact factor: 4.617

Review 3.  The meninges: new therapeutic targets for multiple sclerosis.

Authors:  Abigail E Russi; Melissa A Brown
Journal:  Transl Res       Date:  2014-09-01       Impact factor: 7.012

4.  IFNγ-stimulated dendritic cell exosomes as a potential therapeutic for remyelination.

Authors:  Aya D Pusic; Kae M Pusic; Benjamin L L Clayton; Richard P Kraig
Journal:  J Neuroimmunol       Date:  2013-11-09       Impact factor: 3.478

5.  A new formulation of cannabidiol in cream shows therapeutic effects in a mouse model of experimental autoimmune encephalomyelitis.

Authors:  Sabrina Giacoppo; Maria Galuppo; Federica Pollastro; Gianpaolo Grassi; Placido Bramanti; Emanuela Mazzon
Journal:  Daru       Date:  2015-10-21       Impact factor: 3.117

6.  Intranasal Immunization with DOTAP Cationic Liposomes Combined with DC-Cholesterol Induces Potent Antigen-Specific Mucosal and Systemic Immune Responses in Mice.

Authors:  Rui Tada; Akira Hidaka; Naoko Iwase; Saeko Takahashi; Yuki Yamakita; Tomoko Iwata; Shoko Muto; Emi Sato; Noriko Takayama; Emi Honjo; Hiroshi Kiyono; Jun Kunisawa; Yukihiko Aramaki
Journal:  PLoS One       Date:  2015-10-06       Impact factor: 3.240

7.  Pathways and gene networks mediating the regulatory effects of cannabidiol, a nonpsychoactive cannabinoid, in autoimmune T cells.

Authors:  Ewa Kozela; Ana Juknat; Fuying Gao; Nathali Kaushansky; Giovanni Coppola; Zvi Vogel
Journal:  J Neuroinflammation       Date:  2016-06-03       Impact factor: 8.322

8.  Puerarin transport across a Calu-3 cell monolayer - an in vitro model of nasal mucosa permeability and the influence of paeoniflorin and menthol.

Authors:  Lin Zhang; Shou-Ying Du; Yang Lu; Chang Liu; Zhi-Hao Tian; Chang Yang; Hui-Chao Wu; Zhen Wang
Journal:  Drug Des Devel Ther       Date:  2016-07-08       Impact factor: 4.162

Review 9.  Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting.

Authors:  Fabio Sonvico; Adryana Clementino; Francesca Buttini; Gaia Colombo; Silvia Pescina; Silvia Stanisçuaski Guterres; Adriana Raffin Pohlmann; Sara Nicoli
Journal:  Pharmaceutics       Date:  2018-03-15       Impact factor: 6.321

10.  Expression of ACE2 in Human Neurons Supports the Neuro-Invasive Potential of COVID-19 Virus.

Authors:  Jiaxi Xu; Eric Lazartigues
Journal:  Cell Mol Neurobiol       Date:  2020-07-04       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.